A phase I study of trimetrexate (NSC 352122) administered by 5-day continuous intravenous infusion
Authors:
- 1 October 1989
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 24 (4) , 246-250
Abstract
Trimetrexate (TMTX) is a potent inhibitor of dihydrofolate reductase that circumvents the transport resistance seen with methotrexate and has a wide spectrum of preclinical activity. A total of 18 patients with advanced cancer were treated in a clinical and pharmacological phase I trial with TMTX given as a continuous 5-day intravenous infusion. Neutropenia, thrombocytopenia and stomatitis were the dose-limiting toxicities at the maximum tolerated dose of 50 mg/m2 per 120 h (10 mg/m2 per day for 5 days). There was one septic death associated with neutropenia. Other toxicities were mild rash, mild nausea and transiently raised serum transminase levels. Significant relationships between the dose given and the AUC of plasma TMTX and the steady-state plasma level were established. Significant, although weak, relationships between the percentage of change in neutrophils and platelets and both the AUC and steady-state plasma level of TMTX were also observed. No objective tumour responses were seen, although six patients had stable disease. The recommended phase II dose for a continuous infusion of trimetrexate is 40 mg/m2 per 120 h.Keywords
This publication has 12 references indexed in Scilit:
- PHARMACOKINETICS OF TRIMETREXATE ADMINISTERED BY 5-DAY CONTINUOUS INFUSION TO PATIENTS WITH ADVANCED CANCER1987
- Uptake and efficacy of trimetrexate (TMQ, 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl] quinazoline), a non-classical antifolate in methotrexate-resistant leukemia cells in vitroBiochemical Pharmacology, 1984
- USE OF A HUMAN-TUMOR CLONING SYSTEM TO EVALUATE ANALOGS OF METHOTREXATE AND MITOXANTRONE1984
- Drug resistance in cancer.1984
- Unstable Methotrexate Resistance in Human Small-Cell Carcinoma Associated with Double Minute ChromosomesNew England Journal of Medicine, 1983
- PATTERNS OF CROSS-RESISTANCE TO THE ANTI-FOLATE DRUGS TRIMETREXATE, METOPRINE, HOMOFOLATE, AND CB3717 IN HUMAN LYMPHOMA AND OSTEO-SARCOMA CELLS RESISTANT TO METHOTREXATE1983
- PHARMACOLOGY AND TOXICITY OF A POTENT NON-CLASSICAL 2,4-DIAMINO QUINAZOLINE FOLATE ANTAGONIST, TRIMETREXATE, IN NORMAL DOGS1982
- Enzymatic assays for 2, 4-diamino-5-methyl-6-[(3, 4, 5-trimethoxyanilino)methyl]quinazoline, a promising new “nonclassical” antifolateJournal of Pharmaceutical Sciences, 1981
- Reporting results of cancer treatmentCancer, 1981
- 2,4-Diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline (TMQ), a potent non-classical folate antagonist inhibitor—IBiochemical Pharmacology, 1979